Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CXC chemokine receptor 7 (CXCR7), also known as ACKR3 and RDC1, is a seven-transmembrane G protein-coupled receptor (GPCR) that primarily binds the chemokines CXCL12 (SDF-1α) and CXCL11 (I-TAC). Unlike classical GPCRs, CXCR7 does not signal through G proteins but instead modulates cellular responses via alternative mechanisms. It acts as a scavenger receptor, internalizing and degrading its ligands, and recruits β-arrestin upon ligand binding, leading to activation of downstream pathways such as ERK/MAPK signaling. CXCR7 is upregulated in various cancers and plays a role in tumor growth, metastasis, and angiogenesis. It is an active area for drug discovery.
β-arrestin recruitment; non-G-protein mediated ERK/MAPK activation
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CXC chemokine receptor 7 (CXCR7).